STOCK TITAN

Cartesian Therapeutics (RNAC) Stock News, Nov 13, 2023

RNAC NASDAQ

Cartesian Therapeutics, Inc. reports news on its late clinical-stage biotechnology work in mRNA-engineered cell therapy for autoimmune diseases. The company's lead asset, Descartes-08, is an autologous BCMA-targeting CAR-T candidate being developed for generalized myasthenia gravis, myositis indications such as dermatomyositis and antisynthetase syndrome, and pediatric autoimmune diseases including juvenile dermatomyositis.

Recurring updates cover clinical program progress across AURORA, TRITON and HELIOS, FDA designations for Descartes-08, financial results and cash runway commentary, corporate presentations and investor conference participation. News also includes Nasdaq employment inducement grants, equity incentive plan activity, and board or committee changes tied to the company's public-company governance.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.04%
Tags

FAQ

What is the current stock price of Cartesian Therapeutics (RNAC)?

Cartesian Therapeutics (RNAC) last closed at $6.08.

What is the market cap of Cartesian Therapeutics (RNAC)?

The market cap of Cartesian Therapeutics (RNAC) is approximately $185.5M.